AMITYVILLE, N.Y., Sep 12, 2003 (BUSINESS WIRE) -- Hi-Tech
Pharmacal Co., Inc. (NASDAQ:HITK) will release its first quarter
fiscal 2004 results on Monday, September 15, 2003. The Company will
hold a conference call to discuss its first quarter results on
Tuesday, September 16, 2003 at 1 p.m. Eastern Time.
To access the conference call, dial toll free 800-901-5213, or
617-786-2962 for international callers, five minutes before the
conference. The passcode of the conference call is 47673672.
A replay of the conference call will be available one hour after
the conference call for one week by calling toll free 888-286-8010, or
617-801-6888 for international callers. The passcode for the replay
Hi-Tech is a specialty pharmaceutical company developing,
manufacturing and marketing branded and generic products for the
general healthcare industry. The Company specializes in difficult to
manufacture liquid and semi-solid dosage forms and produces a range of
sterile ophthalmic, otic and inhalation products. The Company's Health
Care Products Division is a leading developer and marketer of branded
prescription and OTC products for the diabetes marketplace.
Statements concerning future results in this release may
constitute forward-looking statements within the meaning of the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. These statements are based on current expectation and the
current economic environment. These statements involve a number risks
and uncertainties, including but not limited to the impact of
competitive products and pricing, product demand and market
acceptance, new product development, reliance on key strategic
alliances, availability of raw materials, the regulatory environment,
fluctuations in operating results and other risks detailed from time
to time in the Company's filings with the Securities and Exchange
Commission. Actual results could differ materially from those
expressed or implied in the forward-looking statements and these
statements are not guarantees of the future performance.
Hi-Tech Pharmacal Co., Inc.
David Seltzer or Tanya Akimova